[go: up one dir, main page]

WO2007049098A3 - Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide - Google Patents

Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide Download PDF

Info

Publication number
WO2007049098A3
WO2007049098A3 PCT/IB2005/004199 IB2005004199W WO2007049098A3 WO 2007049098 A3 WO2007049098 A3 WO 2007049098A3 IB 2005004199 W IB2005004199 W IB 2005004199W WO 2007049098 A3 WO2007049098 A3 WO 2007049098A3
Authority
WO
WIPO (PCT)
Prior art keywords
related diseases
agent
treatment
beta
therapeutic formulations
Prior art date
Application number
PCT/IB2005/004199
Other languages
English (en)
Other versions
WO2007049098A2 (fr
Inventor
Francine Gervais
Francesco Bellini
Original Assignee
Neurochem Int Ltd
Francine Gervais
Francesco Bellini
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/871,512 external-priority patent/US20050038000A1/en
Priority claimed from US10/871,365 external-priority patent/US7244764B2/en
Priority claimed from US10/871,543 external-priority patent/US7253306B2/en
Priority claimed from US10/871,514 external-priority patent/US7414076B2/en
Priority claimed from US10/871,549 external-priority patent/US20050142191A1/en
Priority claimed from US10/871,537 external-priority patent/US20050031651A1/en
Application filed by Neurochem Int Ltd, Francine Gervais, Francesco Bellini filed Critical Neurochem Int Ltd
Priority to JP2007542367A priority Critical patent/JP2008504372A/ja
Priority to CA002582385A priority patent/CA2582385A1/fr
Priority to EP05858504A priority patent/EP1841460A2/fr
Publication of WO2007049098A2 publication Critical patent/WO2007049098A2/fr
Publication of WO2007049098A3 publication Critical patent/WO2007049098A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention a trait à des procédés et des compositions pharmaceutiques pour le traitement de maladies associées au bêta-amyloïde, y compris la maladie d'Alzheimer. L'invention a trait, par exemple, à un procédé de traitement thérapeutique concomitant d'un sujet, comprenant l'administration d'une quantité efficace d'un premier agent et d'un deuxième agent, ledit premier agent traitant une maladie associée au bêta-amyloïde, la dégénérescence, ou la toxicité cellulaire; et ledit deuxième agent étant un médicament thérapeutique ou un supplément nutritif.
PCT/IB2005/004199 2004-06-18 2005-06-17 Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide WO2007049098A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2007542367A JP2008504372A (ja) 2004-06-18 2005-06-17 β−アミロイド関連疾患の治療のための治療用製剤
CA002582385A CA2582385A1 (fr) 2004-06-18 2005-06-17 Formulations therapeutiques de traitement des affections rattachees a la proteine beta-amyloide
EP05858504A EP1841460A2 (fr) 2004-06-18 2005-06-17 Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
US87161304A 2004-06-18 2004-06-18
US10/871,512 US20050038000A1 (en) 2003-06-23 2004-06-18 Methods and compositions for the treatment of amyloid-and epileptogenesis-associated diseases
US10/871,365 US7244764B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,514 2004-06-18
US10/871,613 2004-06-18
US10/871,549 2004-06-18
US10/871,537 2004-06-18
US10/871,365 2004-06-18
US10/871,543 US7253306B2 (en) 2003-06-23 2004-06-18 Pharmaceutical drug candidates and methods for preparation thereof
US10/871,512 2004-06-18
US10/871,514 US7414076B2 (en) 2003-06-23 2004-06-18 Methods and compositions for treating amyloid-related diseases
US10/871,549 US20050142191A1 (en) 2003-06-23 2004-06-18 Pharmaceutical formulations of amyloid inhibiting compounds
US10/871,543 2004-06-18
US10/871,537 US20050031651A1 (en) 2002-12-24 2004-06-18 Therapeutic formulations for the treatment of beta-amyloid related diseases

Publications (2)

Publication Number Publication Date
WO2007049098A2 WO2007049098A2 (fr) 2007-05-03
WO2007049098A3 true WO2007049098A3 (fr) 2007-10-04

Family

ID=37968188

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/004199 WO2007049098A2 (fr) 2004-06-18 2005-06-17 Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide

Country Status (4)

Country Link
EP (1) EP1841460A2 (fr)
JP (1) JP2008504372A (fr)
CA (1) CA2582385A1 (fr)
WO (1) WO2007049098A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010040232A1 (fr) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Utilisation de scyllo-inositols pour le traitement de troubles liés à la dégénérescence maculaire
CA2739732A1 (fr) * 2008-11-14 2010-05-20 Bellus Health (International) Limited Sels nutritifs organiques, leurs procedes de preparation et leurs utilisations
WO2010096925A1 (fr) * 2009-02-26 2010-09-02 Bellus Health (International) Limited Matériau comestible complété et/ou enrichi en homotaurine, procédés de préparation et utilisations
CA2804215C (fr) 2009-07-22 2019-10-01 Eric Elenko Procedes et compositions de traitement de troubles, ceux-ci etant ameliores par l'activation du recepteur muscarinique
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
JP5934102B2 (ja) 2009-10-30 2016-06-15 レトロトップ、 インコーポレイテッドＲｅｔｒｏｔｏｐｅ， Ｉｎｃ． Ｐｕｆａ誘導体による酸化ストレス障害の緩和
KR102110175B1 (ko) 2011-04-26 2020-05-13 레트로토프 인코포레이티드 Ｐｕｆａ 산화와 관련된 장애
KR102111997B1 (ko) 2011-04-26 2020-05-18 레트로토프 인코포레이티드 Ｐｕｆａ와 관련된 신경퇴행성 질환 및 근육 질환
AU2012249921B2 (en) 2011-04-26 2017-06-08 Biojiva Llc Oxidative retinal diseases
WO2012148927A2 (fr) 2011-04-26 2012-11-01 Retrotope, Inc. Troubles de traitement compromis de l'énergie et déficiences mitochondriales
RU2488388C1 (ru) * 2012-05-24 2013-07-27 Ооо "Валента Интеллект" Фармацевтическая композиция для профилактики и лечения психических, поведенческих, когнитивных расстройств
CN102793694B (zh) * 2012-08-14 2014-06-04 武汉华纳联合药业有限公司 3-氨基-1-丙烷磺酸及其衍生物在制备治疗脑卒中的药物中的应用
JP7048976B2 (ja) 2015-11-23 2022-04-06 レトロトップ、 インコーポレイテッド １，４－ジエン系の部位特異的同位体標識
ITUA20161679A1 (it) * 2016-03-15 2017-09-15 Neuraxpharm Italy S P A Composizione per prevenire e trattare patologie neurodegenerative e disturbi cognitivi
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR20250103804A (ko) 2018-03-08 2025-07-07 인사이트 코포레이션 PI3K-γ 저해제로서의 아미노피라진 다이올 화합물
CN112367970A (zh) * 2018-04-12 2021-02-12 J·大卫格莱斯顿研究所-根据J·大卫格莱斯顿遗嘱的遗嘱信托 用于治疗apoe4/4相关病症的方法
US11046658B2 (en) 2018-07-02 2021-06-29 Incyte Corporation Aminopyrazine derivatives as PI3K-γ inhibitors
US12251375B2 (en) 2018-08-23 2025-03-18 Chong Kun Dang Pharmaceutical Corp. Pharmaceutical preparation having excellent dissolution properties, containing esomeprazole and sodium bicarbonate
NZ773719A (en) 2018-09-28 2022-07-29 Karuna Therapeutics Inc Compositions and methods for treating disorders ameliorated by muscarinic receptor activation
US20220022881A1 (en) * 2018-12-04 2022-01-27 The Brain Protection Company PTY LTD Combinatorial therapies including implantable damping devices and therapeutic agents for treating a condition and associated systems and methods of use
WO2021055670A1 (fr) 2019-09-20 2021-03-25 Avx Corporation Biocapteur électrique à base de cellules somatiques
JP2023514711A (ja) 2020-02-21 2023-04-07 レトロトップ、 インコーポレイテッド 多価不飽和脂肪酸及びその誘導体の同位体修飾方法
US20210353566A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology The use of choline supplementation as therapy for apoe4-related disorders
US12109194B2 (en) 2021-02-05 2024-10-08 Biojiva Llc Synergistic combination therapy for treating ALS

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085093A2 (fr) * 1999-12-23 2001-11-15 Neurochem, Inc. Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide
WO2004058239A1 (fr) * 2002-12-24 2004-07-15 Neurochem (International) Limited Formulations therapeutiques destinees au traitement de maladies liees au peptide beta-amyloide

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001085093A2 (fr) * 1999-12-23 2001-11-15 Neurochem, Inc. Composes et methodes permettant la modulation de l'angiopathie cerebrale amyloide
WO2004058239A1 (fr) * 2002-12-24 2004-07-15 Neurochem (International) Limited Formulations therapeutiques destinees au traitement de maladies liees au peptide beta-amyloide

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KISILEVSKY R ET AL: "ARRESTING AMYLOIDOSIS IN VIVO USING SMALL-MOLECULE ANIONIC SULPHONATES OR SULPHATES: IMPLICATIONS FOR ALZHEIMER'S DISEASE", NATURE MEDICINE, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 1, no. 2, 1 February 1995 (1995-02-01), pages 143 - 148, XP000611547, ISSN: 1078-8956 *
MCGEER EDITH G ET AL: "Clinically tested drugs for Alzheimer's disease.", EXPERT OPINION ON INVESTIGATIONAL DRUGS JUL 2003, vol. 12, no. 7, July 2003 (2003-07-01), pages 1143 - 1151, XP002442171, ISSN: 1354-3784 *
ROCCA PAOLA ET AL: "Donepezil in the treatment of Alzheimer's disease: long-term efficacy and safety.", PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY FEB 2002, vol. 26, no. 2, February 2002 (2002-02-01), pages 369 - 373, XP002442170, ISSN: 0278-5846 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9499480B2 (en) 2006-10-12 2016-11-22 Bhi Limited Partnership Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid

Also Published As

Publication number Publication date
CA2582385A1 (fr) 2005-12-18
JP2008504372A (ja) 2008-02-14
EP1841460A2 (fr) 2007-10-10
WO2007049098A2 (fr) 2007-05-03

Similar Documents

Publication Publication Date Title
WO2007049098A3 (fr) Formulations therapeutiques pour le traitement de maladies associees au beta-amyloide
MXPA05006940A (es) Formulaciones terapeuticas para el tratamiento de enfermedades relacionadas con beta - amiloide.
WO2003096990A3 (fr) Cages proteiques pour l'administration d'agents therapeutiques et d'imagerie medicale
WO2006008639A8 (fr) Traitement combine pour malignites non hematologiques par anticorps anti -ogf-1r
WO2006035434A3 (fr) Oligoribonucleotides et procedes d'utilisation associes pour le traitement de l'alopecie, des insuffisances renales aigues et d'autres maladies
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
GB0211649D0 (en) Organic compounds
WO2004112711A3 (fr) Composition orale a liberation prolongee
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
WO2004028570A3 (fr) Methode de traitement de l'acouphene severe
WO2005005414A3 (fr) Derives de pyrazolyl-indole actifs en tant qu'inhibiteurs de kinase, procede de preparation correspondant et compositions pharmaceutiques les contenant
EP1558220A4 (fr) Compositions orales pour le traitement de maladies
WO2006037031A3 (fr) Formulations et procedes destines au traitement de maladies inflammatoires
MY143795A (en) Tetrahydropyridoindole derivatives
WO2006130679A3 (fr) Composition et methode de traitement de rhinite allergique
WO2006073786A3 (fr) Compositions opthalmiques comprenant un steroide et une cyclosporine pour le traitement de l'oeil sec
MXPA05003253A (es) Nuevos derivados de pirimidinamida y el uso de los mismos.
WO2005014572A8 (fr) Derives de pyrimidylpyrrole pouvant etre utilises comme inhibiteurs de kinases
WO2008105507A1 (fr) Agent thérapeutique pour lésion de la moelle épinière
WO2006115770A3 (fr) Preparations pharmaceutiques d'olazanpine en comprimes a desintegration orale
AU2002357191A1 (en) Derivatives of isoindigo, indigo and indirubin and use in treating cancer
WO2004100893A3 (fr) Methodes de traitement d'affections inflammatoires a l'aide de ct-3 ou de ses analogues
WO2007081486A3 (fr) Administration orale de defensines pour traiter des maladies intestinales
AU2001266289A1 (en) 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
WO2009003694A3 (fr) Procédé de traitement de maladies liées à un dysfonctionnement mitochondrial

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 2007542367

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2005858504

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2582385

Country of ref document: CA

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWP Wipo information: published in national office

Ref document number: 2005858504

Country of ref document: EP